BioXcel: Positive Update on BXCL501 for Dementia Related Agitation

 Review of TRANQUILITY data showed 30 mcg dose met statistical significance across multiple scales

Company initiated supplemental 40 mcg dose cohort to help inform clinical development strategy across the full range of dementia care settings

End of Phase 2 meeting scheduled with U.S. Food and Drug Administration (“FDA”) in Q2 2021

Pivotal Phase 3 program expected to begin in the second half of 2021

https://www.globenewswire.com/news-release/2021/03/03/2186065/0/en/BioXcel-Therapeutics-Provides-Update-on-its-BXCL501-Program-for-the-Acute-Treatment-of-Dementia-Related-Agitation.html